CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Firazyr (icatibant)

Last Updated: July 8, 2020
Result type: Reports
Product Line: Reimbursement Review

Generic Name: icatibant

Brand Name: Firazyr

Manufacturer: Takeda Canada Inc.

Indications: Acute attacks of hereditary angioedema in adolescents and children aged two years and older with C1-esterase inhibitor deficiency

Submission Type: Non-submission

Project Status: Not filed

Recommendation Type: CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer